recently reported incomplete sarcolemmal dystrophin coverage in human patients with severe BMD and intermediate muscular dystrophy (i.e., disease severity greater than typical BMD, but less severe than typical DMD)68 which provides support for the notion that dystrophin uniformity is likely to be a factor in the success of therapeutic interventions in patients. This evidence concerns the gene DMD and Duchenne muscular dystrophy.